Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 24;219(12):1934-1939.
doi: 10.1093/infdis/jiz039.

Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients

Robert Strassl  1 , Konstantin Doberer  1 , Susanne Rasoul-Rockenschaub  2 , Harald Herkner  3 , Irene Görzer  4 , Johannes Philipp Kläger  5 , Ralf Schmidt  4 , Helmuth Haslacher  6 , Martin Schiemann  1 , Farsad A Eskandary  1 , Željko Kikić  1 , Roman Reindl-Schwaighofer  1 , Elisabeth Puchhammer-Stöckl  4 , Georg A Böhmig  1 , Gregor Bond  1
Affiliations

Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients

Robert Strassl et al. J Infect Dis. .

Abstract

Background: Drug-induced immunosuppression in kidney transplant recipients is crucial to prevent allograft rejection, but increases risk for infectious disease. Immunologic monitoring to tailor immunosuppressive drugs might prevent alloreactivity and adverse effects simultaneously. The apathogenic torque teno virus (TTV) reflects the immunocompetence of its host and might act as a potential candidate for a holistic monitoring.

Methods: We screened all 1010 consecutive patients from the prospective Vienna Kidney Transplant Cohort Study for availability of allograft biopsies and adequately stored sera for TTV quantification by polymerase chain reaction.

Results: Patients with acute biopsy-proven alloreactivity according to the Banff classification (n = 33) showed lower levels of TTV in the peripheral blood compared to patients without rejection (n = 80) at a median of 43 days before the biopsy. The risk for alloreactivity decreased by 10% per log level of TTV copies/mL (risk ratio, .90 [95% confidence interval, .84-.97]; P = .005). TTV levels >1 × 106 copies/mL exclude rejection with a sensitivity of 94%. Multivariable generalized linear modeling suggests an independent association between TTV level and alloreactivity.

Conclusions: TTV is a prospective biomarker for risk stratification of acute biopsy-proven alloreactivity in kidney transplant recipients and might be a potential tool to tailor immunosuppressive drug therapy.

Keywords: immunologic monitoring; kidney transplantation; rejection; torque teno virus.

PubMed Disclaimer

References

    1. Andrews LM, Li Y, De Winter BCM, et al. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 2017; 13:1225–36. - PubMed
    1. Focosi D, Antonelli G, Pistello M, Maggi F. Torquetenovirus: the human virome from bench to bedside. Clin Microbiol Infect 2016; 22:589–93. - PubMed
    1. Maggi F, Pifferi M, Fornai C, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol 2003; 77:2418–25. - PMC - PubMed
    1. Schiemann M, Puchhammer-Stockl E, Eskandary F, et al. Torque teno virus load-inverse association with antibody-mediated rejection after kidney transplantation. Transplantation 2017; 101:360–7. - PMC - PubMed
    1. Sis B, Mengel M, Haas M, et al. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10:464–71. - PubMed

Publication types

MeSH terms